trending Market Intelligence /marketintelligence/en/news-insights/trending/Ry8-sQFxbXns_e5ti-O48A2 content esgSubNav
In This List

Imugene, Baker IDI to collaborate on cancer treatment research

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Imugene, Baker IDI to collaborate on cancer treatment research

Imugene Ltd. entered an exclusive agreement with Baker IDI Heart & Diabetes Institute in Melbourne to research, develop and commercialize a portfolio of small molecule arginine modulators for oncology.

Researchers believe that increasing the availability of arginine, a naturally occurring amino acid critical for the activation, growth and survival of the body's own cancer-fighting cells, could help restore the tumor-killing activity of the body's own cancer-fighting cells. Depletion of arginine has been observed in renal cell carcinoma and acute myeloid leukemia patients.

Under the agreement, Imugene will pay no up-front costs for the exclusive, worldwide rights to Baker IDI's arginine modulators for drug research, development and commercialization for oncology and cancer treatment. In return, Baker IDI will receive 1.5% of net revenues generated from approved cancer therapies using the technology.

The first proof of concept studies are scheduled to begin in 2017. A new patent protecting the compounds in the field of oncology has been filed with the Australian Patent Office.